CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of diffuse large B-cell lymphoma.
  
  LEARNING OBJECTIVES

  • Apply available clinical research findings to the formation of evidence-based therapeutic approaches for the treatment of newly diagnosed and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
  • Appraise published Phase III clinical trial data documenting the benefit of CD79b-targeted therapy as a component of first-line treatment for DLBCL, and consider the implications of these findings for current clinical management algorithms.
  • Appreciate long-term efficacy and safety data with FDA-approved chimeric antigen receptor (CAR) T-cell therapies directed at CD19, and identify patients with R/R DLBCL for whom this approach may be appropriate.
  • Assess recently presented Phase III clinical trial data documenting the benefit of various CAR T-cell platforms as second-line therapy for R/R DLBCL, and consider the significance of these findings in routine clinical decision-making.
  • Review pivotal clinical trial findings leading to the FDA approval of other novel compounds with unique mechanisms of action for R/R DLBCL, and identify patients for whom treatment with these approaches would be appropriate.
  • Evaluate the mechanism of action of and available clinical trial data with bispecific antibodies targeting CD20 × CD3 in patients with DLBCL, and consider the potential clinical role of these agents.
  • Compare and contrast the side effects associated with available and emerging therapeutic strategies for DLBCL, and formulate supportive care strategies to minimize and manage these toxicities.
  • Recall ongoing clinical studies evaluating novel agents and strategies for DLBCL, and counsel appropriate patients regarding the potential benefits of trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  Presentations Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty and moderator reported relevant financial relationships with ineligible entities:
  
  Gilles Salles, MD, PhD
  Service Chief, Lymphoma Service
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Advisory Committee: AbbVie Inc, Bristol-Myers Squibb Company, Celgene Corporation, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MorphoSys, Novartis, Takeda Pharmaceuticals USA Inc; Consulting Agreements: AbbVie Inc, ATB Therapeutics, Debiopharm, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Kite, A Gilead Company, Miltenyi Biotec, Molecular Partners, Nordic Nanovector, RAPT Therapeutics; Data and Safety Monitoring Board/Committee: BeiGene Ltd; Nonrelevant Financial Relationship: Educational Events hosted by Bayer HealthCare Pharmaceuticals, Regeneron Pharmaceuticals Inc.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from ADC Therapeutics, Genmab, and Karyopharm Therapeutics.
  
  Release date: February 2023
  Expiration date: February 2024